Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (NCT05281471)
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
🩺 Plain-English Summary (8th-Grade Level)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Who can join: Review the eligibility criteria below.
Location: The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- The University of South Alabama, Mitchell Cancer Institute — Mobile, Alabama
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
- UC San Diego Health - Moores Cancer Center — La Jolla, California
- Hoag Gynecologic Oncology — Newport Beach, California
- UCI Health Chao Family Comprehensive Cancer Center — Orange, California
- AdventHealth Cancer Institute — Orlando, Florida
- Sarasota Memorial Healthcare System — Sarasota, Florida
- Women's Cancer Associates with Women's Care Florida — St. Petersburg, Florida
- Emory University — Atlanta, Georgia
- Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Holy Cross Hospital — Silver Spring, Maryland
- University of Michigan — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Washington University School of Medicine — St Louis, Missouri
- Mercy Hospital St. Louis — St Louis, Missouri
- Women's Cancer Center of Nevada — Las Vegas, Nevada
- Center of Hope — Reno, Nevada
- Stony Brook Cancer Center — Stony Brook, New York
- Levine Cancer Institute — Charlotte, North Carolina
- East Carolina University — Greenville, North Carolina
- Atrium Health Wake Forest Baptist, Comprehensive Cancer Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- OhioHealth Research Institute — Columbus, Ohio
- Kettering Health — Kettering, Ohio
📞 Contact the Study Coordinator
Phone: (251) 445-9834
Email: swhite@southalabama.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Platinum-resistant Ovarian Cancer
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) — Phoenix, Arizona
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Anchorage, Alaska
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors — Little Rock, Arkansas
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer — El Segundo, California
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Platinum-resistant Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.